CoChat

Hypertensive myocardial fibrosis

Open access
Cuspidi, Cesare, Ciulla, Michele, Zanchetti, Alberto · 2006 · Nephrology Dialysis Transplantation
Cited by 84

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

A variety of cardiac structural and functional changes, such as increased left ventricular mass (LVM), left atrial and aortic root enlargement, LV dysfunction, impairment of coronary reserve and prolonged ventricular repolarization, have been described in patients with long-standing arterial hypertension [1,2]. However, subtle modifications in LV structure and geometry may occur also in the early phases of the natural history of essential hypertension [3]. Among these manifestations of target organ damage, most attention has been devoted to LV hypertrophy (LVH), because the prevalence of this phenotype is relatively high and is associated with an increased risk of cardiovascular morbidity and mortality [4,5]. Normal myocardium is composed of cardiac myocytes, tethered to an extracellular matrix of fibrillar collagen; they represent one-third of all cells, with cells other than cardiomyocytes accounting for the remaining two-thirds [6]. A large body of evidence indicates that myocardial structure in hypertensive LVH is affected by two key pathological processes: myocyte hypertrophy and a progressive accumulation of fibrous tissue within the cardiac interstitium [7–9]. Thus, in hypertensive LVH, a homogeneous tissue becomes heterogeneous, as a disproportionate accumulation of cells other than cardiomyocytes occurs, accounting for the development of alterations in myocardial texture. Both post-mortem and endomyocardial biopsy studies have shown that along with a variable increase in LVM, the collagen volume fraction (CVF) of the myocardium is increased in hypertensive patients compared with their normotensive counterparts; moreover, histologic evidence of fibrosis such as focal scars, endocardial or interstitial fibrosis has been found during the early phases of hypertension in patients with a mild degree of LVH [10–12]. Both haemodynamic and non-haemodynamic factors play a synergic role in myocardial fibrosis. Chronic pressure overload stimulates both procollagen gene expression and collagen protein synthesis leading to excessive collagen deposition and fibrosis. Two types of findings suggest that besides the pressure overload, other biological variables may contribute to myocardial fibrosis: (a) fibrosis has been found not only in the left ventricle but also in the right one in post-mortem studies of hypertensive individuals with LVH [13]; (b) the ability of different antihypertensive drugs to regress fibrosis in hypertensives with biopsy-proven myocardial fibrosis, is independent of their antihypertensive efficacy [14]. Myocardial fibrosis is a complex phenomenon reflecting the loss of the physiological reciprocal regulation between stimulatory (e.g. angiotensin II, endothelin I, catecholamines, aldosterone, basic fibroblast growth factor, insulin-like growth factor, etc.) and inhibitory factors (prostaglandins, nitric oxide, natriuretic peptides etc.) acting on the turnover of fibrillar collagen [15]. Several lines of evidence support a role for angiotensin II as a critical factor responsible for myocardial fibrosis. Angiotensin II induces fibroblast proliferation, alteration of fibrillar collagen turnover and stimulation of aldosterone, leading to accumulation of collagen type I and III fibres and fibrosis [16]. This accumulation results in a distortion of tissue structure, which is responsible for the increase in myocardial stiffness leading to diastolic dysfunction, a substrate for ventricular arrhythmias, and ultimately to systolic dysfunction [17]. Cardiac biopsy is certainly the gold standard in this regard, but for obvious reasons endomyocardial biopsies for antemortem measurements of the myocardial collagen volume fraction (CVF) have been limited to a small number of patients. The possibility that cardiac fibrosis can be reliably detected and monitored over time by non-invasive techniques is supported by a growing body of evidence in this field. Different methodologic approaches such as biochemical markers of collagen synthesis and degradation, cardiac hormones and ultrasonographic procedures have been developed and validated against CVF as measured in endomyocardial biopsies. Serum markers of collagen turnover can be classified according to their specific action: (1) markers of collagen synthesis [carboxy-terminal propeptide of procollagen type I (PIP), carboxy-terminal propeptide of procollagen type III (PIIIP)]; (2) markers of collagen degradation [carboxy-terminal telopeptide of collagen type I (CITP)]; (3) markers of collagen degradation inhibition [tissue inhibitor of matrix metalloproteinases type I (TIMP I)]; (4) markers of fibroblast activity [transforming growth factor β1 (TGF β1)]. Serum markers of collagen synthesis or degradation have been investigated and found to be altered in hypertension [18]. In particular, numerous studies have shown that serum PIP was significantly higher in hypertensives with LVH than in normotensive controls [19–21]. It correlated with CVF on endomyocardial bi

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfi237

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 84

Metadata

Authors
Cuspidi, C., Ciulla, M., & Zanchetti, A.
Venue
Nephrology Dialysis Transplantation
Published
2005-11-01
Volume
21
Issue
1
Pages
20-23
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2162681171
Cited by
84
References
2
FWCI
1.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypertensive myocardial fibrosis. https://app.cochat.ai/papers/10.1093/ndt/gfi237
The paper
Cuspidi, C., Ciulla, M., & Zanchetti, A. (2006). Hypertensive myocardial fibrosis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfi237

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.